Related references
Note: Only part of the references are listed.FTY720 attenuates excitotoxicity and neuroinflammation
Raffaela Cipriani et al.
JOURNAL OF NEUROINFLAMMATION (2015)
The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
Georgios Tsivgoulis et al.
PLOS ONE (2015)
New management algorithms in multiple sclerosis
Per Soelberg Sorensen
CURRENT OPINION IN NEUROLOGY (2014)
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease
Alba Di Pardo et al.
HUMAN MOLECULAR GENETICS (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations
F Bagnato et al.
ARCHIVES OF NEUROLOGY (2005)
Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis
CM Dalton et al.
JOURNAL OF NEUROLOGY (2004)
Role of MRI in multiple sclerosis I: Inflammation and lesions
R Zivadinov et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2004)
Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes
M Filippi et al.
NEUROLOGY (2001)
Share Paper
